Results 181 to 190 of about 163,674 (312)
The efficacy of preoperative evolocumab-rosuvastatin combination therapy in patients with ST-elevation myocardial infarction. [PDF]
Li H, Dong H, Bao S, Wang X, Fu Z.
europepmc +1 more source
ABSTRACT Introduction D‐dimers are produced by lysis of cross‐linked fibrin. In children, D‐dimer testing is used to evaluate disseminated intravascular coagulation (DIC) and some inflammatory states, but its use is not validated for screening or ruling out suspected venous thromboembolic events (VTE).
Rabab Al Dawood +4 more
wiley +1 more source
Primary antiphospholipid syndrome complicated by recurrent acute ST-elevation myocardial infarction: a case report. [PDF]
Huo L, Hou C, Cao C, Peng X, Liu J.
europepmc +1 more source
ABSTRACT Background Longitudinal data on in‐hospital glycaemia from Australian hospitals are limited. Aims: The aim of this study was to evaluate the efficacy and safety of current inpatient management strategies in New South Wales hospitals and to compare hospital‐acquired complication (HAC) rates in patients with and without diabetes.
Barbara Depczynski +2 more
wiley +1 more source
Acute ST-Elevation Myocardial Infarction (STEMI) Diagnoses in a Biventricular-Paced ECG. [PDF]
Govil D +4 more
europepmc +1 more source
ABSTRACT Background AVEIR DR, an industry‐first dual‐chamber leadless pacemaker (LP), provides continuous atrioventricular synchrony through implant‐to‐implant (i2i) communication between atrial and ventricular LP devices. It is important to evaluate the early real‐world comparative safety of AVEIR DR LP.
Monica Lo +10 more
wiley +1 more source
ST-elevation myocardial infarction halves expected survival in cancer patients even after effective revascularization. [PDF]
Garin D +5 more
europepmc +1 more source
Focus on ST elevation myocardial infarction [PDF]
openaire +2 more sources
Nemolizumab in prurigo nodularis up to 100 weeks: OLYMPIA LTE interim analysis
In this interim analysis of the OLYMPIA long‐term extension trial, nemolizumab exhibited sustained efficacy and was well tolerated through 100 weeks, with most adverse events being mild/moderate. Patients showed clinically meaningful improvements in core signs and symptoms.
Franz J. Legat +22 more
wiley +1 more source
Cardioprotective therapies for ST-elevation myocardial infarction: the emerging role of thyroid hormone: a narrative review. [PDF]
Grigoriou K +7 more
europepmc +1 more source

